Anika Therapeutics
Anika Therapeutics' revenue fell 5.9% to $113 million in fiscal 2025. Its operating margin was −9.8%, down from −4.2% a year earlier. Free cash flow was $4 million. It paid out $9 million in dividends and buybacks, 217% of free cash flow. The diluted share count fell 2.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Anika Therapeutics does
Anika makes medical products from hyaluronic acid, a substance found naturally in the body's joints and tissues. Its products go to orthopedic surgeons and other physicians, mainly to treat joint pain and to repair tendons and cartilage.
It reports two product groups. Osteoarthritis pain management includes Monovisc and Orthovisc, which are injections for joint pain, and Cingal. Regenerative solutions includes the Integrity Implant System, a scaffold used in rotator cuff and other tendon repairs, and Hyalofast, which is awaiting FDA approval. The company lists competition as a risk.
In October 2024 the company decided to focus on these two groups. It sold its Arthrosurface business in October 2024 and its Parcus Medical business in March 2025. It filed an application with the FDA for Hyalofast in October 2025 and is working on a response to the deficiencies the FDA listed in January 2026. At the end of 2025 it had 235 full-time employees in the United States and Europe.
Its biggest risks, as it describes them
- Relying on a small number of customers for much of its osteoarthritis pain management revenue.
- Approval of Hyalofast and Cingal in the U.S. is uncertain, and the FDA has already listed deficiencies for Hyalofast.
- Relying on a small number of suppliers for key raw materials and components.
- Disruption to its manufacturing, and product liability claims if its products harm patients.
Income statement
From fiscal 2016 to 2021, earnings per share fell 33.5% a year and net income 33.9% a year, while buybacks cut the share count by 3%. Anika Therapeutics then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 124 | 121 | 95 | 79 | 81 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.7x | 6.1x | 5.3x | 4.9x | 4.7x |
| Quick ratio | 4.5x | 4.7x | 4.5x | 3.9x | 3.9x |
Cash flow
Projections
Project Anika Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $264,308 of Anika Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Gary P FischettiDirector | Bought | 1,000 | $20.32 | $20,320 | Form 4 |
| Aug 3, 2026 | Gary P FischettiDirector | Bought | 1,000 | $20.75 | $20,750 | Form 4 |
| May 1, 2026 | John B Henneman IIIDirector | Bought | 5,000 | $14.66 | $73,300 | Form 4 |
| Apr 30, 2026 | Stephen D. GriffinPresident and CEO, Director | Bought | 12,200 | $12.29 | $149,938 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 0.1% | −2.7% | −2.0% |
| Altman Z'' | 8.59 | 7.22 | 6.68 |
| Accruals ratio | −26.1% | −26.1% | −11.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Fail | Pass |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Anika Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Anika Therapeutics | FY25 | −5.9% | −9.8% | 3.9% | — | — | — | |
| OraSure Technologies | FY25 | −38.1% | −62.6% | −46.3% | — | — | — | Compare |
| Outset Medical | FY25 | 5.1% | −55.8% | −39.4% | −88.0% | — | 6 | Compare |
| Owlet | FY25 | 35.4% | −7.8% | −10.5% | — | — | 5 | Compare |
| Sanara MedTech | FY25 | 19.0% | 7.1% | 2.1% | 13.0% | 2.6x | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 103 | 113 | 106 | 115 | 130 | 148 | 114 | 121 | 120 | 113 |
| Revenue growth | 11.2% | 9.7% | −6.9% | 8.6% | 13.8% | 13.3% | −23.0% | 6.1% | −0.7% | −5.9% |
| Gross profit | 79 | 86 | 74 | 86 | 69 | 83 | 73 | 82 | 76 | 64 |
| Research and development | 11 | 19 | 18 | 17 | 23 | 27 | 18 | 22 | 26 | 26 |
| Operating income | 51 | 46 | 22 | 34 | −28 | 3 | 4 | 1 | −5 | −11 |
| Net income | 32 | 32 | 19 | 27 | −24 | 4 | −15 | −83 | −56 | −11 |
| Diluted EPS (US$) | 2.15 | 2.11 | 1.27 | 1.89 | −1.69 | 0.28 | −1.02 | −5.64 | −3.83 | −0.76 |
| Diluted shares (millions) | 15 | 15 | 15 | 14 | 14 | 15 | 15 | 15 | 15 | 14 |
| Cash flow | ||||||||||
| Cash from operations | 24 | 41 | 35 | 37 | 13 | 8 | 4 | −2 | 5 | 11 |
| Capital expenditure | 14 | 9 | 5 | 3 | 2 | 5 | 8 | 5 | 8 | 7 |
| Free cash flow | 10 | 32 | 30 | 34 | 11 | 3 | −3 | −7 | −2 | 4 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 25 | 0 | 30 | 30 | 0 | 0 | 0 | 5 | 11 | 10 |
| Acquisitions | 0 | 0 | 0 | 0 | 95 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 6 | 11 | 6 | 5 | 11 | 14 | 15 | 13 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 125 | 157 | 159 | 185 | 98 | 124 | 121 | 95 | 79 | 81 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 240 | 283 | 279 | 331 | 366 | 348 | 349 | 271 | 203 | 190 |
| Total liabilities | 18 | 19 | 15 | 42 | 93 | 60 | 64 | 58 | 49 | 47 |
| Shareholders' equity | 223 | 264 | 264 | 288 | 272 | 287 | 286 | 212 | 154 | 144 |
| Margins and ratios | ||||||||||
| Gross margin | 76.8% | 75.9% | 70.4% | 74.9% | 52.9% | 56.1% | 64.3% | 68.3% | 63.4% | 56.6% |
| Operating margin | 49.0% | 40.3% | 20.6% | 29.9% | −21.7% | 1.8% | 3.2% | 0.7% | −4.2% | −9.8% |
| Net margin | 31.5% | 28.1% | 17.7% | 23.7% | −18.4% | 2.8% | −13.1% | −68.4% | −47.0% | −9.6% |
| Free cash flow margin | 10.1% | 28.1% | 28.7% | 29.8% | 8.8% | 2.2% | −2.7% | −6.0% | −1.9% | 3.9% |
| Rule of 40 (growth + FCF margin) | 21.2% | 37.8% | 21.7% | 38.4% | 22.6% | 15.5% | −25.7% | 0.1% | −2.7% | −2.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 15.0% | 13.1% | 7.1% | 9.8% | −8.6% | 1.5% | −5.2% | −33.2% | −30.8% | −7.3% |
| Return on assets | 13.7% | 12.2% | 6.7% | 8.9% | −6.9% | 1.2% | −4.3% | −26.7% | −23.8% | −5.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |